Celgene (NASDAQ:CELG) is a biopharmaceutical company that focuses on niche drugs serving cancer and immune diseases. While the patient pools can be smaller, the treatments also can be very high-margin products and thus make up for reach with profitability.
Celgene kicked off 2012 with serious buzz thanks to impressive reviews at a JPMorgan healthcare conference that resulted in a slew of upgrades from top Wall Street firms. However, some investors are worried that CELG stock has all the profits already baked in.
Still, the long-term potential of its cancer cures and drug pipeline might give you reason to consider a position.